Medgenics Announces Results of 2013 Annual Meeting of Stockholders
MISGAV, Israel & SAN FRANCISCO--(BUSINESS WIRE)-- Medgenics, Inc. (NYSE MKT: MDGN and AIM: MEDU, MEDG) (the Company or Medgenics),, the developer of a novel technology for the sustained production and delivery of therapeutic proteins in patients using their own tissue, today announces that all resolutions proposed at the Companys Annual Meeting of Stockholders held yesterday were duly passed.
Each of the current directors of the Company, Dr. Sol J. Barer, Dr. Eugene A. Bauer, Mr. Isaac Blech, Dr. Alastair Clemow, Mr. Joseph J. Grano, Jr., Mr. Joel S. Kanter, Dr. Stephen D. McMurray and Dr. Andrew L. Pearlman, was reelected to the Board of Directors.
Stockholders also approved an amendment of the Companys Stock Incentive Plan, increasing the number of shares authorized to be issued under the plan by 1,700,000 shares.
Stockholders also approved, on an advisory basis, the compensation of the executive officers of the Company. Additionally, the option to request the stockholders to vote, on an advisory basis, on executive compensation every three years received the most votes cast.
Stockholders also ratified the appointment of Kost Forer Gabbay & Kasierer, a member of Ernst & Young Global, to serve as the Company's independent registered public accounting firm for the year ended December 31, 2013.
Final voting tallies are subject to certification by the Company's inspector of elections and will be included in the Company's report, which is to be filed with the Securities and Exchange Commission within the next week.
About Medgenics (MDGN)
Medgenics is developing and commercializing Biopump", a proprietary tissue-based platform technology for the sustained production and delivery of therapeutic proteins using the patient's own skin biopsy for the treatment of a range of chronic diseases including anemia, hepatitis C and hemophilia.
Dr. Andrew L. Pearlman
Phone: +972 4 902 8900
Anne Marie Fields
Adam Michael/Joanne Shears/Jamie Hooper
Phone: +44 207 398 7719
Nomura Code Securities (NOMAD & Joint Broker)
Jonathan Senior/Giles Balleny
Phone: +44 207 776 1200
SVS Securities plc (Joint Broker)
Phone: +44 207 638 5600
Source: Medgenics, Inc.Copyright Business Wire 2013